Editor’s Note: Green and red arrows refer to intraday stock price movement. NEW YORK (TheStreet) — CHANGE IN RATINGS Biogen Idec upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $75 price target. New analyst expects Tysabri to perform above consensus expectations. … Click to view a price quote on BIIB . Click to research the Drugs industry.
(read on…)

Related items